BioCryst Pharmaceuticals Acquires Presidio Pharmaceuticals for $101,000,000
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=90f906e5-3cdf-4273-8ed2-60cb435f9d0a&Preview=1 - Date
10/19/2012 - Company Name
Presidio Pharmaceuticals - Mailing Address
1700 Owens Street San Francisco, CA 94158 - Company Description
Presidio is focused on developing novel and established therapeutic modalities and small molecule compounds for the treatment of HIV-1, HCV and other chronic virus infections. - Website
http://www.presidiopharma.com - Transaction Type
M&A - Transaction Amount
$101,000,000 - Transaction Round
- Proceeds Purposes
- M&A Terms
The acquisition will be paid for with all stock.
